Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Competition between Drug Distributors Heats Up in Zhejiang Province

publication date: Mar 24, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Sinopharm Group announced it will acquire Zhejiang Wenling Drug Materials, based in Taizhou, Zhejiang province. Wenling, whose yearly revenues have averaged 1.1 billion RMB ($168 million) over the past three years, generates 90% of its business by selling to hospitals. The acquisition amped up a competition in Zhejiang between Sinopharm and its chief drug rival in the drug distribution sector, Shanghai Pharmaceuticals Holding. More details....

Stock Symbols: (HK: 1099) (SHE: 601607)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...